Key facts: Sanofi's Q3 sales are expected to be 2% below estimates, while adjusted profit should meet forecasts. The October 24 earnings call will discuss U.S. drug pricing strategies.
Moins d'1 minute de lecture
- Sanofi's Q3 sales are expected to be 2% below estimates, while adjusted profit should meet forecasts. The October 24 earnings call will discuss U.S. drug pricing strategies.1
- Sanofi's stock rose 2.07% on Friday, driven by positive trends in European markets, influenced by service sector activity and producer prices in the Eurozone.2
- Sanofi India announced a distribution partnership with Emcure Pharmaceuticals in July, aimed at expanding Emcure's therapy portfolio.3